The P3H2 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from human Raji Burkitt’s lymphoma B cells, featuring heterogeneous P3H2 gene disruption across the pool. This format minimizes clonal artifacts and provides a robust loss-of-function model to interrogate P3H2 functions in a lymphoid environment.
The Raji cell line, originating from an EBV-positive Burkitt’s lymphoma, harbors the hallmark MYC-IGH translocation t(8;14) that drives constitutive MYC expression and aggressive lymphomagenesis. As mature B lymphocytes, these cells also mediate humoral immunity, making them a versatile platform for dissecting oncogenic signaling and tumor-host interactions.
P3H2 functions as a collagen prolyl 3-hydroxylase within the endoplasmic reticulum, where it forms a heteromeric complex with CRTAP and peptidyl-prolyl isomerase PPIB to hydroxylate proline residues on nascent collagen chains, predominantly type IV and type V. This modification is indispensable for collagen triple helix thermal stability and subsequent extracellular matrix (ECM) supramolecular assembly. Transcriptional regulation of P3H2 occurs through TGF-?¨CSMAD2/3, SP1, HIF-1??, and MITF pathways. Downstream, 3-hydroxylated collagens dictate integrin-mediated cell adhesion and ECM organization, processes further refined by chaperones FKBP10 and HSP47. Loss of P3H2 activity thereby compromises collagen secretion and matrix integrity, underlying connective tissue pathologies such as high myopia and osteogenesis imperfecta.
In the Raji B-cell context, P3H2 knockout enables dissection of its potential non-collagenic roles and its contribution to lymphoma microenvironment biology. Although collagen synthesis is atypical in lymphocytes, Raji cells express integrins that interact with ECM substrates; thus, P3H2 loss may perturb adhesion, migration, and stromal signaling crosstalk. This model offers a unique opportunity to investigate how a collagen-modifying enzyme influences B-cell behavior, immune synapse formation, and tumor-stroma dynamics, shedding light on previously unrecognized connections between ECM regulation and lymphoid malignancies.
Key research applications include confirmation of P3H2 disruption through Western blotting and RT-qPCR, direct measurement of collagen prolyl 3-hydroxylation levels via tandem mass spectrometry, and visualization of P3H2 subcellular distribution or ECM architecture using immunofluorescence. Functional assays such as cell-ECM adhesion assays and flow cytometric profiling of integrin subunits (e.g., ITGA2, ITGB1) can quantify adhesion alterations. Furthermore, drug sensitivity screens can identify compounds that restore collagen hydroxylation or target ECM-dependent survival signals in B-cell neoplasms. For additional information or technical support, please contact Ascent Research.
